仿制药-话题@MedSci

#仿制药#

261篇内容 | 5541人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1261474, encodeId=e95b12614e436, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA正努力推进复杂仿制药的发展, objectType=article, longId=161094, objectId=24891610946a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24891610946a, replyNumber=0, likeNumber=57, createdTime=2019-02-27, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24891610946a, moduleTitle=FDA正努力推进复杂仿制药的发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24891610946a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261473, encodeId=2f3012614e37f, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=浙江鼓励仿制药研发生产及时纳入采购目录, objectType=article, longId=161078, objectId=81901610e875, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81901610e875, replyNumber=0, likeNumber=51, createdTime=2019-02-27, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81901610e875, moduleTitle=浙江鼓励仿制药研发生产及时纳入采购目录, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81901610e875)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261472, encodeId=003f12614e2b5, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA发布新审评通路指导草案鼓励仿制药竞争, objectType=article, longId=160763, objectId=6d0b160e63bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d0b160e63bb, replyNumber=0, likeNumber=65, createdTime=2019-02-23, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d0b160e63bb, moduleTitle=FDA发布新审评通路指导草案鼓励仿制药竞争, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d0b160e63bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261471, encodeId=d72e12614e1fa, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=辉瑞的Avastin生物仿制药——ZIRABEV在欧洲获批治疗多个转移性肿瘤, objectType=article, longId=160659, objectId=32b11606595c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32b11606595c, replyNumber=0, likeNumber=65, createdTime=2019-02-22, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32b11606595c, moduleTitle=辉瑞的Avastin生物仿制药——ZIRABEV在欧洲获批治疗多个转移性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32b11606595c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261470, encodeId=8fa012614e0a8, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=北京为仿制药研发部分买单, objectType=article, longId=160182, objectId=177b16018237, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=177b16018237, replyNumber=0, likeNumber=82, createdTime=2019-02-18, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=177b16018237, moduleTitle=北京为仿制药研发部分买单, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=177b16018237)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261469, encodeId=f333126146966, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=Coherus宣布与AbbVie达成全球和解，确保其Adalimumab生物仿制药CHS-1420商业化的权利, objectType=article, longId=159211, objectId=6a41159211ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a41159211ca, replyNumber=0, likeNumber=49, createdTime=2019-01-31, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a41159211ca, moduleTitle=Coherus宣布与AbbVie达成全球和解，确保其Adalimumab生物仿制药CHS-1420商业化的权利, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a41159211ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261468, encodeId=66861261468b4, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=年销售额达180亿美元的修美乐将失去市场专属权，仿制药预计一年内占据市场的一半, objectType=article, longId=159001, objectId=47a61590015d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47a61590015d, replyNumber=0, likeNumber=71, createdTime=2019-01-28, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47a61590015d, moduleTitle=年销售额达180亿美元的修美乐将失去市场专属权，仿制药预计一年内占据市场的一半, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47a61590015d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261467, encodeId=db7c126146e82, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=安徽鼓励仿制药研发全国首仿有重奖, objectType=article, longId=158786, objectId=4353158e86e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4353158e86e4, replyNumber=0, likeNumber=56, createdTime=2019-01-26, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4353158e86e4, moduleTitle=安徽鼓励仿制药研发全国首仿有重奖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4353158e86e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261466, encodeId=ed72126146635, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=安徽鼓励仿制药研发全国首仿奖励200万元, objectType=article, longId=158777, objectId=d070158e7780, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d070158e7780, replyNumber=0, likeNumber=74, createdTime=2019-01-26, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d070158e7780, moduleTitle=安徽鼓励仿制药研发全国首仿奖励200万元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d070158e7780)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261465, encodeId=9b4d126146595, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=从仿制药挑战专利案例观策略, objectType=article, longId=157494, objectId=cf9315e4946e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf9315e4946e, replyNumber=0, likeNumber=60, createdTime=2019-01-08, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf9315e4946e, moduleTitle=从仿制药挑战专利案例观策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf9315e4946e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261464, encodeId=3c5d1261464b6, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=十二部门：加强仿制药技术攻关，促进仿制药替代使用, objectType=article, longId=157201, objectId=10ce15e2017e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10ce15e2017e, replyNumber=0, likeNumber=87, createdTime=2019-01-04, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10ce15e2017e, moduleTitle=十二部门：加强仿制药技术攻关，促进仿制药替代使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10ce15e2017e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261463, encodeId=e4b81261463bb, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=Inflam Bowel Dis：炎症性肠病患者从单抗治疗药物转换为生物仿制药CT-P13后的药物存活和免疫原性, objectType=article, longId=157182, objectId=d67915e182c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d67915e182c6, replyNumber=0, likeNumber=80, createdTime=2019-01-03, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d67915e182c6, moduleTitle=Inflam Bowel Dis：炎症性肠病患者从单抗治疗药物转换为生物仿制药CT-P13后的药物存活和免疫原性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d67915e182c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261462, encodeId=ae6812614624e, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=12部委发文，促进仿制药供应保障, objectType=article, longId=157097, objectId=51ef15e097f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51ef15e097f8, replyNumber=0, likeNumber=80, createdTime=2019-01-02, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51ef15e097f8, moduleTitle=12部委发文，促进仿制药供应保障, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51ef15e097f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261461, encodeId=b9741261461c3, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=报告：仿制药将加快替代原研药优质仿制药企将受益, objectType=article, longId=156168, objectId=31db15616869, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31db15616869, replyNumber=0, likeNumber=76, createdTime=2018-12-21, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31db15616869, moduleTitle=报告：仿制药将加快替代原研药优质仿制药企将受益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31db15616869)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261460, encodeId=eb521261460b0, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=山西：仿制药纳入医保支付范围, objectType=article, longId=156134, objectId=c8cc15613439, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8cc15613439, replyNumber=0, likeNumber=70, createdTime=2018-12-20, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8cc15613439, moduleTitle=山西：仿制药纳入医保支付范围, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8cc15613439)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261459, encodeId=e53a1261459c1, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA撤销仿制药安全标签提案药企将免于不良反应诉讼?, objectType=article, longId=156014, objectId=6d251560147a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d251560147a, replyNumber=0, likeNumber=70, createdTime=2018-12-19, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d251560147a, moduleTitle=FDA撤销仿制药安全标签提案药企将免于不良反应诉讼?, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d251560147a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261458, encodeId=d9af126145813, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=Ann Rheum Dis：换药或不换药？从初始药强制换为依那西普生物仿制药全国性指南的结果, objectType=article, longId=153505, objectId=e6e515350516, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6e515350516, replyNumber=0, likeNumber=59, createdTime=2018-11-16, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6e515350516, moduleTitle=Ann Rheum Dis：换药或不换药？从初始药强制换为依那西普生物仿制药全国性指南的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6e515350516)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261457, encodeId=cab1126145e0e, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=广东出台改革完善仿制药供应保障及使用政策实施方案, objectType=article, longId=153348, objectId=ae2915334860, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae2915334860, replyNumber=0, likeNumber=84, createdTime=2018-11-14, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae2915334860, moduleTitle=广东出台改革完善仿制药供应保障及使用政策实施方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae2915334860)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261456, encodeId=deef12614560e, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药等于低端药？北大教授李玲：二者不能划等号, objectType=article, longId=152740, objectId=1c5d152e40fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c5d152e40fd, replyNumber=0, likeNumber=42, createdTime=2018-11-05, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c5d152e40fd, moduleTitle=仿制药等于低端药？北大教授李玲：二者不能划等号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c5d152e40fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261455, encodeId=f23412614551a, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA仿制药一致性评价指导原则, objectType=article, longId=152545, objectId=dd1715254575, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd1715254575, replyNumber=0, likeNumber=78, createdTime=2018-11-03, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd1715254575, moduleTitle=FDA仿制药一致性评价指导原则, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd1715254575)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

仿制药

2020-05-29

drwjr (审核中...)

前往app查看评论内容

#仿制药#

FDA正努力推进复杂仿制药的发展

2019-02-27

drwjr (审核中...)

前往app查看评论内容

#仿制药#

浙江鼓励仿制药研发生产及时纳入采购目录

2019-02-27

drwjr (审核中...)

前往app查看评论内容

#仿制药#

FDA发布新审评通路指导草案鼓励仿制药竞争

2019-02-23

drwjr (审核中...)

前往app查看评论内容

#仿制药#

辉瑞的Avastin生物仿制药——ZIRABEV在欧洲获批治疗多个转移性肿瘤

2019-02-22

drwjr (审核中...)

前往app查看评论内容

#仿制药#

北京为仿制药研发部分买单

2019-02-18

drwjr (审核中...)

前往app查看评论内容

#仿制药#

Coherus宣布与AbbVie达成全球和解，确保其Adalimumab生物仿制药CHS-1420商业化的权利

2019-01-31

drwjr (审核中...)

前往app查看评论内容

#仿制药#

年销售额达180亿美元的修美乐将失去市场专属权，仿制药预计一年内占据市场的一半

2019-01-28

drwjr (审核中...)

前往app查看评论内容

#仿制药#

安徽鼓励仿制药研发全国首仿有重奖

2019-01-26

drwjr (审核中...)

前往app查看评论内容

#仿制药#

安徽鼓励仿制药研发全国首仿奖励200万元

2019-01-26

drwjr (审核中...)

前往app查看评论内容

#仿制药#

从仿制药挑战专利案例观策略

2019-01-08

drwjr (审核中...)

前往app查看评论内容

#仿制药#

十二部门：加强仿制药技术攻关，促进仿制药替代使用

2019-01-04

drwjr (审核中...)

前往app查看评论内容

#仿制药#

Inflam Bowel Dis：炎症性肠病患者从单抗治疗药物转换为生物仿制药CT-P13后的药物存活和免疫原性

2019-01-03

drwjr (审核中...)

前往app查看评论内容

#仿制药#

12部委发文，促进仿制药供应保障

2019-01-02

drwjr (审核中...)

前往app查看评论内容

#仿制药#

报告：仿制药将加快替代原研药优质仿制药企将受益

2018-12-21

drwjr (审核中...)

前往app查看评论内容

#仿制药#

山西：仿制药纳入医保支付范围

2018-12-20

drwjr (审核中...)

前往app查看评论内容

#仿制药#

FDA撤销仿制药安全标签提案药企将免于不良反应诉讼?

2018-12-19

drwjr (审核中...)

前往app查看评论内容

#仿制药#

Ann Rheum Dis：换药或不换药？从初始药强制换为依那西普生物仿制药全国性指南的结果

2018-11-16

drwjr (审核中...)

前往app查看评论内容

#仿制药#

广东出台改革完善仿制药供应保障及使用政策实施方案

2018-11-14

drwjr (审核中...)

前往app查看评论内容

#仿制药#

仿制药等于低端药？北大教授李玲：二者不能划等号

2018-11-05

drwjr (审核中...)

前往app查看评论内容

#仿制药#

FDA仿制药一致性评价指导原则

2018-11-03

科室
- - 订阅+
  - 更多科室
工具
服务